Cleaved-NOTCH2 (D1733) Antibody

What specifically does the Cleaved-NOTCH2 (D1733) Antibody detect?

The Cleaved-NOTCH2 (D1733) Antibody specifically detects endogenous levels of fragment of activated Notch 2 protein resulting from cleavage adjacent to Aspartic acid 1733. This antibody recognizes the intracellular domain (NICD) that is released following proteolytic processing rather than the full-length NOTCH2 protein. The antibody has been designed to target the cleaved form resulting from γ-secretase-mediated proteolysis, allowing researchers to specifically monitor Notch signaling activation in experimental systems .

What species reactivity has been validated for this antibody?

The Cleaved-NOTCH2 (D1733) Antibody has confirmed reactivity with Human, Mouse, and Rat samples. Cross-reactivity analysis has demonstrated consistent performance across these three mammalian species, making it suitable for comparative studies. The antibody recognizes conserved epitopes within the 1684-1733 amino acid region of NOTCH2 across these species, enabling consistent detection in multi-species experimental designs .

What are the validated applications for Cleaved-NOTCH2 (D1733) Antibody?

This antibody has been validated for multiple experimental applications including:

The antibody has shown particularly strong performance in Western blot applications for detecting the cleaved fragment at approximately 110 kDa .

How should I optimize Western blot conditions for detecting cleaved NOTCH2?

For optimal Western blot detection of cleaved NOTCH2:

• Protein extraction: Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors to preserve the cleaved fragments.

• Sample preparation: Include 10-20 μg of total protein per lane for cell lysates.

• Gel separation: Use 8% SDS-PAGE gels for optimal resolution of the approximately 110 kDa cleaved NOTCH2 fragment.

• Transfer conditions: Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer containing 20% methanol.

• Blocking: Block with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Start with 1:1000 dilution in 5% BSA/TBST overnight at 4°C.

• Washing: Wash 3-4 times with TBST, 5-10 minutes each.

• Secondary antibody: Use anti-rabbit HRP-conjugated secondary antibody at 1:5000 dilution.

• Detection: Use enhanced chemiluminescence detection systems with exposure times of 30 seconds to 5 minutes .

What positive controls should be included when working with this antibody?

When using the Cleaved-NOTCH2 (D1733) Antibody, include these validated positive controls:

• Cell lines known to express activated NOTCH2:

  • 293 cells (human embryonic kidney cells)

  • KB cells (human carcinoma cells)

• Tissue samples with documented NOTCH2 activation:

  • Human liver tissue samples

  • Mouse kidney tissue

  • Rat spleen tissue

• NOTCH pathway activation controls:

  • Cells treated with γ-secretase inhibitors (negative control)

  • Cells transfected with constitutively active NOTCH2 constructs (positive control)

  • Jagged1 or Delta1 ligand-stimulated cells (physiological positive control)

These controls provide reference points for antibody reactivity and help validate experimental findings .

How can I distinguish between cleaved and full-length NOTCH2 in my experiments?

To differentiate between cleaved and full-length NOTCH2:

• Molecular weight comparison: Full-length NOTCH2 appears at approximately 265 kDa, while the cleaved intracellular domain (NICD) is detected at approximately 110 kDa.

• Subcellular fractionation: Perform nuclear/cytoplasmic fractionation - cleaved NOTCH2 should be enriched in nuclear fractions while full-length NOTCH2 is predominantly membrane-associated.

• Dual antibody approach: Use a separate antibody targeting the extracellular domain alongside the Cleaved-NOTCH2 (D1733) Antibody in parallel experiments.

• Inhibitor controls: Treat samples with γ-secretase inhibitors (e.g., DAPT) to prevent cleavage and compare band patterns.

• Stimulus experiments: Analyze time-course experiments following Notch ligand stimulation to observe the appearance of cleaved fragments and reduction of full-length protein .

How can Cleaved-NOTCH2 (D1733) Antibody be utilized to study NOTCH pathway dysregulation in disease models?

The antibody can be employed in disease model research through:

• Comparative analysis of cleavage patterns in normal versus diseased tissues:

  • In Alagille syndrome samples (ALGS2, caused by NOTCH2 mutations)

  • In cancer cells with aberrant NOTCH signaling

  • In developmental disorders affecting NOTCH-dependent organogenesis

• Pharmacological intervention studies:

  • Measuring effects of γ-secretase inhibitors on NOTCH2 cleavage

  • Evaluating novel compounds targeting NOTCH pathway components

• Genetic model analysis:

  • in NOTCH2 knockdown/knockout models

  • in models with ligand (JAG1, JAG2, DLL1) mutations

  • in models with altered NOTCH processing machinery

• Correlation studies:

  • Between NOTCH2 cleavage levels and disease progression markers

  • Between target gene expression and cleaved NOTCH2 levels

• Therapeutic response monitoring:

  • Evaluating NOTCH pathway targeting in preclinical and clinical samples .

What methodological approaches can be used to study NOTCH2 processing dynamics using this antibody?

To investigate NOTCH2 processing dynamics:

• Pulse-chase experiments:

  • Track NOTCH2 processing over time using metabolic labeling

  • Combine with immunoprecipitation using the Cleaved-NOTCH2 (D1733) Antibody

• Live-cell imaging approaches:

  • Correlate with fluorescently tagged NOTCH2 constructs

  • Perform fixed-cell immunofluorescence at defined timepoints using this antibody

• Stimulus-response kinetics:

  • Analyze time-course of ligand-induced NOTCH2 cleavage

  • Compare different ligands (JAG1, JAG2, DLL1) for differential processing

• Proteasome inhibition experiments:

  • Analyze cleaved NOTCH2 stability with proteasome inhibitors

  • Track degradation kinetics of the cleaved fragment

• Co-immunoprecipitation studies:

  • Identify protein complexes associated with cleaved NOTCH2

  • Study how these interactions change under different experimental conditions .

How can Cleaved-NOTCH2 (D1733) Antibody be integrated into multi-parameter flow cytometry analyses?

For incorporating this antibody into flow cytometry protocols:

• Cell permeabilization optimization:

  • Use methanol-based permeabilization for optimal nuclear antigen detection

  • Compare Triton X-100, saponin, and methanol fixation methods for best signal-to-noise ratio

• Multi-color panel design:

  • Pair with antibodies against NOTCH target genes (HES1, HEY1)

  • Combine with cell cycle markers (Ki67, phospho-histone H3)

  • Include lineage/differentiation markers relevant to your cell system

• Signal amplification strategies:

  • Employ biotin-streptavidin systems for enhanced detection

  • Use fluorochrome-conjugated secondary antibodies with bright fluorophores

• Validation controls:

  • Include NOTCH2 knockdown cells as negative controls

  • Use constitutively active NOTCH2 transfectants as positive controls

• Data analysis approaches:

  • Gate on cells with nuclear localization of cleaved NOTCH2

  • Perform correlation analysis with other NOTCH pathway components

  • Apply dimensionality reduction techniques (tSNE, UMAP) for complex datasets .

What are common technical challenges when using Cleaved-NOTCH2 (D1733) Antibody and how can they be addressed?

Common challenges and their solutions include:

Additionally, ensure proper storage of the antibody at -20°C for long-term or 4°C for short-term to maintain reactivity .

How should results be interpreted when differential cleavage patterns are observed across experimental conditions?

When interpreting variations in NOTCH2 cleavage patterns:

• Quantitative assessment:

  • Normalize cleaved NOTCH2 signal to total NOTCH2 expression

  • Calculate cleavage ratios (cleaved/full-length) for accurate comparisons

  • Apply statistical analyses appropriate for the experimental design

• Biological context consideration:

  • Correlate cleavage variations with known modulators of NOTCH signaling

  • Consider cell type-specific processing differences

  • Evaluate effects of differentiation state or cell cycle phase

• Verification approaches:

  • Confirm with alternative detection methods (qPCR of NOTCH target genes)

  • Validate with functional assays of NOTCH activity (luciferase reporters)

  • Perform intervention studies to establish causality

• Alternative splicing awareness:

  • Consider the potential presence of NOTCH2 splice variants

  • Verify the antibody's reactivity to specific isoforms

  • Include isoform-specific controls when available .

How can discrepancies between Cleaved-NOTCH2 detection and downstream signaling effects be reconciled?

When facing inconsistencies between cleaved NOTCH2 detection and downstream effects:

• Time-course consideration:

  • Examine temporal relationships between cleavage and target gene expression

  • Account for potential delays between NOTCH2 cleavage and transcriptional responses

• Co-factor analysis:

  • Evaluate expression/activation of NOTCH co-activators (MAML1, p300)

  • Assess potential competitive inhibition from other NOTCH family members

• Post-translational modification assessment:

  • Investigate phosphorylation status affecting NICD activity

  • Consider ubiquitination-mediated regulation of cleaved NOTCH2 stability

• Pathway crosstalk evaluation:

  • Analyze interference from intersecting signaling pathways (Wnt, Hedgehog)

  • Consider cell-specific signal integration mechanisms

• Technical verification:

  • Confirm nuclear translocation of cleaved NOTCH2 (necessary for transcriptional activity)

  • Validate antibody specificity using genetic approaches (CRISPR/Cas9 editing) .

How does Cleaved-NOTCH2 (D1733) Antibody compare with antibodies targeting other NOTCH pathway components for research applications?

Comparative analysis of NOTCH pathway antibodies:

This comparison highlights the specific utility of Cleaved-NOTCH2 (D1733) Antibody for directly measuring pathway activation rather than just expression levels .

What advanced techniques can be combined with Cleaved-NOTCH2 (D1733) Antibody for comprehensive pathway analysis?

Advanced methodological combinations include:

• ChIP-seq applications:

  • Map genome-wide binding sites of cleaved NOTCH2

  • Identify novel target genes through immunoprecipitation with this antibody

  • Correlate binding patterns with transcriptional outcomes

• Proximity ligation assays:

  • Detect in situ interactions between cleaved NOTCH2 and transcriptional co-factors

  • Visualize subcellular localization of these interaction events

  • Quantify interaction frequencies across different experimental conditions

• Mass spectrometry integration:

  • Identify post-translational modifications on cleaved NOTCH2

  • Discover novel interaction partners through immunoprecipitation-mass spectrometry

  • Map proteome-wide changes following NOTCH2 activation

• Super-resolution microscopy:

  • Track cleaved NOTCH2 nuclear localization patterns at nanoscale resolution

  • Analyze co-localization with transcriptional machinery components

  • Observe dynamic changes in nuclear distribution during signaling events

• Single-cell technologies:

  • Combine with single-cell Western blot for heterogeneity analysis

  • Integrate with single-cell RNA-seq to correlate cleavage with transcriptional profiles

  • Apply in spatial transcriptomics applications to map activation patterns in tissues .

How can researchers integrate computational approaches with experimental data generated using this antibody?

Computational integration strategies include:

• Pathway modeling approaches:

  • Incorporate cleaved NOTCH2 quantitative data into computational models of NOTCH signaling

  • Simulate pathway behavior under various perturbations

  • Generate testable hypotheses about pathway dynamics

• Machine learning applications:

  • Train algorithms to recognize patterns in cleaved NOTCH2 distribution in imaging data

  • Develop predictive models correlating cleavage levels with cellular outcomes

  • Identify novel biomarkers associated with NOTCH2 activation states

• Network analysis:

  • Map interaction networks centered on cleaved NOTCH2

  • Identify key nodes influencing pathway output

  • Discover feedback mechanisms regulating NOTCH2 processing

• Multi-omics data integration:

  • Correlate cleaved NOTCH2 levels with transcriptomic, proteomic, and epigenomic datasets

  • Generate integrated signatures of NOTCH pathway activation

  • Identify context-specific effects of NOTCH2 cleavage

• Patient data correlation:

  • Analyze cleaved NOTCH2 patterns in patient samples

  • Correlate with clinical parameters and outcomes

  • Develop stratification approaches based on NOTCH2 activation profiles .

What considerations are important when using this antibody for tissue-specific NOTCH2 activation studies?

Key considerations for tissue-specific applications:

• Tissue-specific expression patterns:

  • NOTCH2 is prominently expressed in brain, heart, kidney, lung, skeletal muscle, and liver

  • Embryonic tissues show ubiquitous expression with developmental regulation

  • Optimize antibody concentration based on known expression levels in target tissue

• Fixation and processing optimization:

  • For neural tissues: brief 4% PFA fixation preserves epitope accessibility

  • For liver and kidney: reduce fixation time to avoid epitope masking

  • For muscle: consider specialized fixatives to maintain tissue architecture

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (citrate buffer, pH 6.0) for most tissues

  • For heavily fixed tissues, try enzyme-based retrieval (proteinase K)

  • Optimize retrieval time based on tissue type and fixation duration

• Background reduction strategies:

  • For tissues with high endogenous peroxidase: include additional quenching steps

  • For tissues with high biotin levels: use biotin blocking systems

  • For tissues with high autofluorescence: consider Sudan Black B treatment

• Counterstaining selection:

  • Choose counterstains that highlight relevant tissue architecture

  • For co-localization studies, select compatible fluorophores with minimal spectral overlap .

How can Cleaved-NOTCH2 (D1733) Antibody be utilized to study mechanisms of Alagille syndrome and related disorders?

Research applications for Alagille syndrome studies:

• Genetic variant analysis:

  • Compare cleaved NOTCH2 levels in cells expressing different ALGS2-associated NOTCH2 variants

  • Assess processing efficiency of mutant NOTCH2 proteins

  • Correlate cleavage patterns with functional consequences

• Developmental model systems:

  • Analyze NOTCH2 cleavage patterns during embryonic development in animal models

  • Study tissue-specific processing defects in organs affected by Alagille syndrome

  • Track temporal changes in NOTCH2 activation during critical developmental windows

• Patient-derived samples:

  • Analyze liver biopsies from ALGS2 patients for altered NOTCH2 processing

  • Compare cleaved NOTCH2 patterns with JAG1 mutation cases (ALGS1)

  • Correlate processing defects with clinical phenotype severity

• Therapeutic testing platforms:

  • Evaluate compounds that might rescue processing defects

  • Assess gene therapy approaches for restoring normal NOTCH2 cleavage

  • Screen for small molecules that might bypass cleavage requirements

• Organ-specific analysis:

  • Focus on bile duct development and NOTCH2 processing

  • Investigate cardiac and vascular tissues affected in ALGS2

  • Examine skeletal development and NOTCH2 activation patterns .

What methodological approaches can researchers use to study relationships between NOTCH2 cleavage and cancer progression?

For cancer research applications:

• Human tumor sample analysis:

  • Compare cleaved NOTCH2 levels between tumor and adjacent normal tissues

  • Correlate activation patterns with tumor grade, stage, and patient outcomes

  • Assess heterogeneity of NOTCH2 activation within tumors

• Cancer cell line models:

  • Establish baseline cleaved NOTCH2 levels across cancer cell line panels

  • Correlate with invasiveness, drug resistance, and stem-like properties

  • Manipulate NOTCH2 cleavage and assess phenotypic consequences

• Stromal interaction studies:

  • Analyze NOTCH2 activation in cancer-associated fibroblasts

  • Study juxtacrine signaling between tumor and stromal cells

  • Evaluate NOTCH2 cleavage in tumor-associated immune cells

• Drug response correlations:

  • Monitor changes in cleaved NOTCH2 following treatment with chemotherapeutics

  • Assess NOTCH pathway inhibitor efficacy using cleaved NOTCH2 as a biomarker

  • Identify resistance mechanisms involving altered NOTCH2 processing

• Metastasis models:

  • Track cleaved NOTCH2 levels during epithelial-mesenchymal transition

  • Compare primary and metastatic sites for differential NOTCH2 activation

  • Evaluate the role of NOTCH2 cleavage in circulating tumor cells and cancer stem cells .

What modifications to standard immunoprecipitation protocols are needed for optimal results with Cleaved-NOTCH2 (D1733) Antibody?

Optimized immunoprecipitation protocol adaptations:

• Lysis buffer composition:

  • Use NP-40 or CHAPS-based buffers (1%) to maintain protein interactions

  • Include protease inhibitors (PMSF, leupeptin, aprotinin, pepstatin A)

  • Add phosphatase inhibitors (sodium orthovanadate, sodium fluoride)

  • Consider including deubiquitinase inhibitors (N-ethylmaleimide)

• Antibody binding conditions:

  • Pre-clear lysates with Protein A/G beads (1 hour at 4°C)

  • Use 2-5 μg antibody per 500 μg total protein

  • Incubate overnight at 4°C with gentle rotation

  • Add fresh Protein A/G beads for 2-3 hours at 4°C

• Washing optimization:

  • Perform 4-5 washes with decreasing salt concentration

  • Include 0.1% detergent in wash buffers

  • Maintain cold temperature throughout washing steps

  • Use gentle inversion rather than vortexing

• Elution strategies:

  • For Western blot analysis: direct elution in Laemmli buffer at 95°C

  • For mass spectrometry: consider peptide elution with immunogen

  • For activity assays: use gentle elution with excess peptide

• Controls and validation:

  • Include IgG control immunoprecipitations

  • Validate with NOTCH2 knockout/knockdown samples

  • Confirm specificity with pre-incubation using blocking peptide .

How should researchers optimize immunofluorescence protocols for detecting nuclear localized cleaved NOTCH2?

Immunofluorescence optimization strategies:

• Fixation method selection:

  • Primary recommendation: 4% paraformaldehyde for 10-15 minutes

  • Alternative for better nuclear antigen detection: methanol fixation at -20°C for 10 minutes

  • Combine with 0.1-0.2% Triton X-100 permeabilization post-fixation

• Antigen retrieval considerations:

  • For PFA-fixed samples: 10mM citrate buffer (pH 6.0) heat treatment

  • For formalin-fixed tissues: protease-based retrieval may improve nuclear signal

  • Optimize duration based on sample thickness and fixation time

• Blocking parameters:

  • Use 5-10% normal serum (species of secondary antibody)

  • Include 0.3% Triton X-100 in blocking solution

  • Add 1% BSA to reduce non-specific binding

  • Extend blocking to 1-2 hours at room temperature

• Antibody incubation:

  • Dilute primary antibody 1:50-1:200 in blocking buffer

  • Incubate overnight at 4°C in humidified chamber

  • Use fluorophore-conjugated anti-rabbit secondary at 1:500-1:1000

  • Include DAPI or Hoechst counterstain for nuclear visualization

• Signal enhancement and imaging:

  • Consider tyramide signal amplification for weak signals

  • Use confocal microscopy for precise nuclear localization

  • Capture z-stacks to verify intranuclear versus perinuclear distribution

  • Employ deconvolution for improved resolution .

What considerations are important when designing multiplexed immunohistochemistry panels that include Cleaved-NOTCH2 (D1733) Antibody?

Multiplexed IHC design considerations:

• Antibody panel selection criteria:

  • Choose antibodies from different host species when possible

  • Select markers with distinct subcellular localizations

  • Include pathway components upstream and downstream of NOTCH2

  • Consider markers for specific cell types of interest

• Epitope retrieval compatibility:

  • Determine if all antibodies in panel are compatible with same retrieval method

  • If not, consider sequential staining with interim retrieval steps

  • Test retrieval optimization with single antibodies before multiplexing

• Fluorophore selection and compensation:

  • Choose fluorophores with minimal spectral overlap

  • Include single-color controls for spectral unmixing

  • Assign brightest fluorophores to least abundant targets

  • Consider photobleaching properties for imaging sequence

• Signal amplification strategies:

  • Apply tyramide signal amplification (TSA) for weak signals

  • Use polymer detection systems for enhanced sensitivity

  • Consider quantum dot labeling for multiplexed brightfield

• Validation and controls:

  • Include tissue with known positive and negative regions

  • Perform staining with each antibody individually first

  • Run parallel single-plex and multiplex to verify consistent detection

  • Include appropriate isotype controls for each primary antibody .

How can Cleaved-NOTCH2 (D1733) Antibody be integrated into single-cell analysis workflows?

Single-cell integration approaches:

• Flow cytometry adaptations:

  • Optimize fixation and permeabilization for intracellular/nuclear antigens

  • Combine with surface markers for cell type identification

  • Use fluorescence-activated cell sorting (FACS) to isolate cleaved NOTCH2-positive populations

  • Include viability dyes to exclude dead cells

• Mass cytometry (CyTOF) incorporation:

  • Conjugate antibody with rare earth metals

  • Design panels with up to 40 parameters

  • Include markers for cell cycle, differentiation, and other signaling pathways

  • Apply dimensionality reduction for data visualization

• Single-cell Western blot applications:

  • Deposit cells in microwell arrays

  • Perform in-well lysis and protein separation

  • Probe with Cleaved-NOTCH2 antibody

  • Quantify at single-cell resolution

• Imaging mass cytometry:

  • Apply metal-conjugated antibodies to tissue sections

  • Ablate tissue with laser and analyze metal signatures

  • Achieve subcellular resolution in tissue context

  • Preserve spatial relationships between cells

• Integration with single-cell sequencing:

  • Sort cells based on cleaved NOTCH2 status before sequencing

  • Correlate protein levels with transcriptional profiles

  • Identify gene signatures associated with NOTCH2 activation

  • Apply cellular indexing methods for combined proteomic and transcriptomic profiling .

What approaches can be used to study temporal dynamics of NOTCH2 cleavage in living systems?

Temporal dynamics investigation methods:

• Real-time reporter systems:

  • Design split fluorescent protein reporters linked to NOTCH2 and its cleavage site

  • Create FRET-based sensors detecting conformational changes upon cleavage

  • Develop luciferase complementation assays responsive to NOTCH2 processing

  • Establish stable cell lines expressing these reporters alongside validation with the antibody

• Optogenetic control:

  • Utilize light-inducible NOTCH2 activation systems

  • Combine with live-cell imaging and fixed timepoint antibody validation

  • Control spatial activation patterns with directed light stimulation

  • Measure kinetics of pathway activation and deactivation

• Microfluidic approaches:

  • Design chambers for controlled ligand presentation

  • Perform on-chip fixation at precise timepoints

  • Implement antibody staining in microfluidic devices

  • Correlate with real-time imaging of fluorescent reporters

• In vivo imaging correlates:

  • Use intravital microscopy with fluorescent reporters in animal models

  • Validate with tissue collection and antibody staining at defined timepoints

  • Employ tissue clearing techniques for whole-organ imaging

  • Correlate in vivo dynamics with fixed tissue antibody detection

• Biosensor development:

  • Design synthetic receptors reporting on γ-secretase activity

  • Create NOTCH2 constructs with incorporated detection elements

  • Develop antibody-based biosensors for real-time monitoring

  • Validate sensor outputs with conventional antibody detection methods .

How might Cleaved-NOTCH2 (D1733) Antibody be utilized in the development of targeted therapies affecting the NOTCH pathway?

Applications in therapeutic development:

• Target validation approaches:

  • Validate NOTCH2 processing as a therapeutic target in disease models

  • Correlate cleavage levels with disease phenotypes

  • Identify contexts where NOTCH2 inhibition may be beneficial

  • Distinguish NOTCH2-specific effects from pan-NOTCH effects

• Compound screening applications:

  • Develop high-content screening assays using the antibody

  • Screen for compounds that modulate NOTCH2 cleavage

  • Distinguish between inhibitors of different processing steps

  • Validate hits with orthogonal assays of pathway activity

• Therapeutic antibody development:

  • Use as a benchmark for therapeutic antibodies targeting NOTCH2

  • Develop companion diagnostics for NOTCH-targeting therapies

  • Monitor target engagement in preclinical models

  • Assess pathway modulation in response to treatment

• Biomarker development:

  • Establish cleaved NOTCH2 as a potential predictive biomarker

  • Correlate baseline levels with response to pathway-targeting agents

  • Develop standardized assays for clinical sample analysis

  • Create reference standards for quantitative assessment

• Combination therapy assessment:

  • Evaluate NOTCH2 cleavage changes with various drug combinations

  • Identify synergistic interactions affecting pathway activation

  • Monitor resistance mechanisms involving altered processing

  • Develop rational combination strategies based on pathway dynamics .